معرفی
Dr. Abdul Hamood serves as Professor in the Graduate School of Biomedical Sciences at Texas Tech University Health Sciences Center, where his research centers on Pseudomonas aeruginosa pathogenesis and biofilm inhibition strategies. His work bridges molecular microbiology and translational therapeutics, with recent expansions into gut-brain axis mechanisms for pain management.
Dr. Hamood completed his PhD at the University of Missouri Columbia (1985) followed by postdoctoral training at the University of Rochester School of Medicine (1990).
His research program investigates virulence gene regulation in bacterial pathogens while developing novel antimicrobial approaches. Current projects examine pyocin-based wound therapies, biofilm-dispersing gels, and dietary compounds that modulate neuropathic pain through gut microbiome interactions. This dual focus on fundamental bacterial mechanisms and therapeutic applications defines his interdisciplinary approach.
Recent publications reveal two distinct trajectories: high-impact microbiology work on P. aeruginosa pathogenesis in journals like Canadian Journal of Microbiology, and collaborative nutrition-pharmacology studies on ginger compounds for pain management in Frontiers in Pharmacology.
His scientific recognition includes:
- Dean's Basic Science Teaching - Yr 1 Award, TTUHSC (2015)
Dr. Hamood maintains an active research pipeline through multiple funded projects including a $500,000 USDA grant (as Co-PI) for neuropathic pain research and several industry-sponsored antimicrobial development programs. His mentorship is evidenced by five student presentations at the 2022 Student Research Week covering topics from pyocin therapies to vaginal microbiome dynamics.
Though unnamed, his laboratory functions as a hub for bacterial pathogenesis research with specialized capabilities in biofilm quantification, animal wound models, and microbiome analysis through industry partnerships. Current work focuses on translating pyocin research into clinical applications and identifying microbial metabolites that mediate pain pathways.
